ClinicalTrials.gg
CompletedNCT03433898Updated Dec 19, 2025Results posted

This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

An Early Phase 1 interventional study of Ezabenlimab and BI 754111 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Boehringer Ingelheim · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
146
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objectives of the BI 754091 monotherapy dose-finding part (Part I) of the trial are to investigate the following items in advanced solid tumours:

  • Safety, tolerability, and pharmacokinetics (PK) of BI 754091 as monotherapy.
  • Maximum tolerated dose (MTD) and/or recommended dose (RD) of BI 754091 monotherapy.

The main objectives of the Combination dose-finding part (Part II) of the trial are to investigate the following items in advanced solid tumours:

  • Safety, tolerability, and PK of the combination treatment of BI 754091 and BI 754111.
  • MTD and/or RD of the combination treatment of BI 754091 and BI 754111.

The main objectives of the expansion part (Part III) of the trial are:

  • To further investigate the safety, tolerability, and PK of the RD of BI 754091 and BI 754111 combination in patients with gastric/esophagogastric junction cancer, esophageal cancer, hepatocellular cancer or non-small cell lung cancer (NSCLC)
  • To explore the efficacy of the RD of the combination of BI 754091 and BI 754111 in patients with gastric/esophagogastric junction cancer, esophageal cancer, hepatocellular cancer or NSCLC
02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 146 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Of full age (according to local legislation) at the time of signing of the form (ICF)
  • Women of (WOCBP)1 with negative serum pregnancy test at screening and men able to father a child, who agree to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. The requirement of contraception does not apply to women of no childbearing potential but they must have an evidence of such at screening
  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
  • Patients with according to v1.1
  • Conditions specific to respective part of the trial:

    • Part I (BI 754091 dose-finding part):

      • Patients with a confirmed diagnosis of advanced, unresectable, and/or solid tumours (any type)
      • For whom no therapy of proven efficacy exists, or who are not amenable to standard therapies.
      • Previous treatment with an mAb is allowed as long as the last administration of the anti PD-1 mAb on the previous treatment is a minimum of 28 days prior to the first BI 754091 treatment.
    • Part II (Combination dose-finding part):

      • Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type)
      • For whom no therapy of proven efficacy exists, or who are not amenable to standard therapies.
      • Previous treatment with an anti-PD-1 mAb is allowed as long as the last administration of the anti PD-1 mAb on the previous treatment is a minimum of 28 days prior to the first BI 754091 treatment.
    • Part III (Expansion part):

      • Cohort A: Patients with gastric/esophagogastric junction cancer, with no prior treatment with anti-PD-1/PD-L1 antibody, and who received at least one line of systemic medical treatment excluding therapy
      • Cohort B: Patients with esophageal cancer with no prior treatment with anti-PD-1/PD-L1 antibody, and who received at least one line of systemic medical treatment excluding adjuvant therapy
      • Cohort C: Patients with hepatocellular cancer with no prior treatment with anti-PD-1/PD-L1 antibody, who received at least one line of systemic medical treatment excluding adjuvant therapy, and whose score is 7 or less
      • Cohort D: Patients with gastric/esophagogastric junction cancer, esophageal cancer, or hepatocellular cancer with a prior treatment with anti-PD-1/PD-L1 antibody
      • Cohort E: squamous or non-squamous NSCLC patients:

        • Without EGFR mutations or ALK rearrangements
        • PD-L1 expression level \<50%
      • All cohorts: Patients with advanced and/or metastatic disease, with at least 1 tumour lesion amenable to , and must be medically fit for biopsy at screening as determined by investigator and willing to undergo a biopsy before first treatment (if adequate archival tissue is not available) and, unless clinically , after 6 weeks on therapy.
  • (ECOG) performance status (PS): 0 to 1 at screening

Exclusion criteria

Exclusion Criteria:

  • Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to study entry or planned within 12 months after screening, e.g. hip replacement
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Previous treatment with study medications in this trial
  • Any or anti-tumour treatment within 4 weeks or 5 half-life periods (whichever is shorter) prior to the initiation of trial treatment
  • Any unresolved toxicities from prior therapy greater than (CTCAE) Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 neuropathy due to prior platinum-based therapy
  • (Part II and III only) Prior treatment with anti-LAG-3 agents
  • Patients with lung cancer that have epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, unless disease has progressed following available EGFR or ALK targeted therapy
  • Presence of other active invasive cancers other than the one treated in this Trial within 5 years Prior to screening, with the exception of appropriately treated basal or squamous-cell carcinoma of the skin or in situ carcinoma of the uterine cervix, or other local tumours considered cured by local treatment
  • Untreated (es) that may be considered active. Patients with previously treated brain metastases may participate provided they are stable (i.e., without evidence of PD by imaging for at least 4 weeks prior to the first dose of trial treatment, and any neurologic symptoms have returned to baseline), and there is no evidence of new or enlarging brain metastases
  • Inadequate organ function or bone marrow reserve as demonstrated by the following laboratory values:

    • \<1.5 x 10\^9/L (\<1500/mm\^3)
    • count \<100 x 10\^9/L (\<100,000/mm\^3)
    • \<9.0 g/dL
    • (ALT) >2.5 times the (ULN) if no demonstrable liver lesion(s) (primary or ) or >5 times ULN in the presence of liver lesion(s)
    • Aspartate aminotransferase (AST) >2.5 times ULN if no demonstrable liver lesion(s) or >5 times ULN in the presence of liver lesion(s)
    • Total >1.5 times ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin >3.0 times ULN or direct bilirubin >1.5 times ULN
    • Serum creatinine (measured by enzymatic assay, Isotope dilution mass spectroscopy [IDMS] standardized Jaffe assay, or non-IDMS Jaffe assay) >1.5 times ULN or estimated (eGFR) \<30mL/min/1.73m\^2 (Chronic Kidney Disease Epidemiology [CKD-EPI] Collaboration equation); confirmation of eGFR is only required when creatinine is >1.5 X ULN
    • (INR) (only tested if clinically indicated) >1.5 times ULN (if treated with anticoagulants, prolonged INR is acceptable)
  • Any of the following cardiac criteria:

    • Mean resting interval (QTc) >470 msec
    • Any abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval
    • Patients with an \<55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF, will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
  • History of pneumonitis within the last 5 years
  • History of severe reactions to other mAbs
  • History of severe hypersensitivity reactions to the ingredients of study drug
  • doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of study treatment
  • Active disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy, or asthma well controlled with steroids
  • Active infection requiring systemic treatment (antibacterial, antiviral, or antifungal therapy) at start of treatment in this trial
  • Known history of (HIV) infection or laboratory evidence of hepatitis virus infection with positive results of surface (HBs) antigen and/or presence of HBc antibody together with HBV-DNA and/or RNA (HIV and hepatitis test results obtained in routine diagnostics are acceptable if done within 14 days before the date). However, for patients with hepatocellular cancer in Part III Cohorts C and D, patients with HBV and/or HCV infection are allowed. Hepatocellular cancer patients in Part III Cohorts C and D with HBV infection must be receiving effective antiviral therapy (viral load \<100 IU/mL)
  • Current or history of interstitial lung disease
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes him/her an unreliable trial patient, unlikely to complete the trial, or unable to comply with the protocol procedures. However, for patients with hepatocellular cancer in Part III Cohorts C and D, past chronic alcohol abuse are allowed
  • Women who are pregnant, nursing, or who plan to become pregnant during the trial
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Part I - ezabenlimab 240 mg

    Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours were administered via intravenous infusion with ezabenlimab 240 milligram (mg) on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab

  • Experimental
    Part II - ezabenlimab 240 mg + BI 754111 400 mg

    Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours were administered via intravenous infusion with ezabenlimab 240 milligram (mg) and BI 754111 400 mg on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab · Drug: BI 754111

  • Experimental
    Part II - ezabenlimab 240 mg + BI 754111 600 mg

    Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours were administered via intravenous infusion with ezabenlimab 240 milligram (mg) and BI 754111 600 mg on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab · Drug: BI 754111

  • Experimental
    Part II - ezabenlimab 240 mg + BI 754111 800 mg

    Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours were administered via intravenous infusion with ezabenlimab 240 milligram (mg) and BI 754111 800 mg on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab · Drug: BI 754111

  • Experimental
    Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort A

    Patients with gastric/esophagogastric junction cancer, with no prior treatment with anti-Programmed cell death protein-1 (PD-1)/Programmed death ligand-1 (PD-L1) antibody, and who had received at least one line of systemic anticancer treatment, excluding adjuvant therapy, were administered via intravenous infusion with ezabenlimab 240 milligram (mg) and BI 754111 600 mg on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab · Drug: BI 754111

  • Experimental
    Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort B

    Patients with esophageal cancer, with no prior treatment with anti-Programmed cell death protein-1 (PD-1)/Programmed death ligand-1 (PD-L1) antibody, and who had received at least one line of systemic anticancer treatment, excluding adjuvant therapy, were administered via intravenous infusion with ezabenlimab 240 milligram (mg) and BI 754111 600 mg on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab · Drug: BI 754111

  • Experimental
    Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort C

    Patients with hepatocellular cancer, with no prior treatment with anti-Programmed cell death protein-1 (PD-1)/Programmed death ligand-1 (PD-L1) antibody, who received at least one line of systemic anticancer treatment, excluding adjuvant therapy, and whose Child-Pugh score is ≤7, were administered via intravenous infusion with ezabenlimab 240 milligram (mg) and BI 754111 600 mg on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab · Drug: BI 754111

  • Experimental
    Part III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D

    Patients with gastric/esophagogastric junction cancer, esophageal cancer, or hepatocellular cancer, with a prior treatment with anti-Programmed cell death protein-1 (PD-1)/Programmed death ligand-1 (PD-L1) antibody, were administered via intravenous infusion with ezabenlimab 240 milligram (mg) and BI 754111 600 mg on day 1 of each 3-week (21 days) cycle. Administration was continued until progressive disease, unacceptable toxicity, other withdrawal criteria, or a maximum treatment duration of 1 year. If the patient was benefiting clinically at 1 year, he/she could continue after a case-by-case review with the sponsor.

    Drug: Ezabenlimab · Drug: BI 754111

Interventions

  • Solution for infusion

    Also known as: BI 754091

  • DrugBI 754111

    Solution for infusion

06

What researchers measure

Primary outcomes

  1. Part I: Maximum Tolerated Dose (MTD) of Ezabenlimab

    MTD is defined as the highest dose for a given schedule expected to cause \<25% risk of the true dose limiting toxicity (DLT) rate being ≥33% during the MTD evaluation period. Haematologic DLTs: any Grade 5 toxicity; neutropenia ≥Grade 4 for \>5 days; any duration Febrile neutropenia; grade 4 thrombocytopenia or Grade 3 with bleeding or requiring platelet transfusions (any Grade); unexplained Grade 4 anaemia or requiring blood transfusions (any Grade). Non-haematological DLTs: aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>3x Upper limit of normal (ULN) and total bilirubin \>2x ULN without cholestasis signs; any duration ≥Grade 4 AST or ALT; any ≥Grade 3 non-haematologic toxicity with exceptions; any Grade 4 or 5 adverse event; any duration any Grade 2 pneumonitis; any Grade 2 uveitis, eye pain, or blurred vision not improving to Grade 1 within 2 weeks or requiring systemic treatment; any ≥Grade 2 toxicity causing inability to administer trial drug on Cycle 2 Day 1.

    Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.

  2. Part I: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)

    Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment) is reported.

    Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.

  3. Part II: MTD of the Ezabenlimab Plus BI 754111 Combination Therapy

    MTD is defined as the highest dose for a given schedule expected to cause \<25% risk of the true DLT rate being ≥33% during the MTD evaluation period. Haematologic DLTs: any Grade 5 toxicity; neutropenia ≥Grade 4 for \>5 days; any duration Febrile neutropenia; grade 4 thrombocytopenia or Grade 3 with bleeding or requiring platelet transfusions (any Grade); unexplained Grade 4 anaemia or requiring blood transfusions (any Grade). Non-haematological DLTs: aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>3x Upper limit of normal (ULN) and total bilirubin \>2x ULN without cholestasis signs; any duration ≥Grade 4 AST or ALT; any ≥Grade 3 non-haematologic toxicity with exceptions; any Grade 4 or 5 adverse event; any duration any Grade 2 pneumonitis; any Grade 2 uveitis, eye pain, or blurred vision not improving to Grade 1 within 2 weeks or requiring systemic treatment; any ≥Grade 2 toxicity causing inability to administer trial drugs on Cycle 2 Day 1.

    Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.

  4. Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)

    Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment) is reported.

    Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.

  5. Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator

    Number of patients with objective response (OR) - confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) Version 1.1 as assessed by the Investigator, is reported. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 49 months.

Secondary outcomes

  1. Part III: Duration of Response

    The duration of response, defined as the interval from the date of first documented PR or CR according to RECIST Version 1.1 as assessed by the Investigator, to the date of progressive disease (PD) or death, is reported. For all patients with an OR, the duration of OR was calculated as follows: * for patients with PD or death: duration of response \[days\] = date of outcome - date of first assessment indicating OR + 1, * for patients without PD or death: duration of response (censored) \[days\] = date of outcome - date of first assessment indicating OR + 1, for patients without disease progression or death. Kaplan-Meier estimates were used to calculate median duration of OR.

    Time frame: From the date of objective response until first date that death or PD has been documented, up to 1362 days.

  2. Part III: Number of Patients With Disease Control

    Number of patients with disease control is reported. Disease control: CR, PR, or stable disease (SD) according to RECIST Version 1.1 as assessed by the Investigator. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 49 months.

  3. Part I: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator

    Number of patients with OR: confirmed CR or PR according to RECIST v1.1 as assessed by the Investigator, is reported. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): 180 days.

  4. Part II: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator

    Number of patients with OR: confirmed CR or PR according to RECIST v1.1 as assessed by the Investigator, is reported. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 389 days.

  5. Part I: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment

    Maximum measured concentration of ezabenlimab in plasma (Cmax) in the first cycle of treatment (21 days following drug administration) is reported.

    Time frame: 5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.

  6. Part II: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment

    Maximum measured concentration of ezabenlimab in plasma (Cmax) in the first cycle of treatment (21 days following drug administration) is reported.

    Time frame: 5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.

  7. Part II: Maximum Measured Concentration of BI 754111 in Plasma (Cmax) in the First Cycle of Treatment

    Maximum measured concentration of BI 754111 in plasma (Cmax) in the first cycle of treatment (21 days following drug administration) is reported.

    Time frame: 5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.

  8. Part I: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment

    Area under the concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) in the first cycle of treatment (21 days following drug administration) is reported.

    Time frame: 5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.

  9. Part II: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment

    Area under the concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) in the first cycle of treatment (21 days following drug administration) is reported.

    Time frame: 5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.

  10. Part II: Area Under the Concentration-time Curve of BI 754111 in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment

    Area under the concentration-time curve of BI 754111 in plasma over the time interval from 0 to 504 hours (AUC0-504) in the first cycle of treatment (21 days following drug administration) is reported.

    Time frame: 5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.

07

Results

Posted Dec 19, 2025
Limitations and caveats
A Cohort E in part III, composed of first line non-small cell lung cancer patients, was also originally planned. However, the clinical development of the combination therapy of BI 754111 and ezabenlimab was concluded early according to protocol due to lack of efficacy of BI 754111 before Cohort E was initiated, so no patient was enrolled in the cohort.

Participant flow

This is a Phase I, open-label, non-randomised trial in patients with advanced solid tumours to investigate safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD) and/or recommended dose (RD) of BI 754091 (ezabenlimab) as monotherapy (part I), safety, tolerability, PK and RD of ezabenlimab and BI 754111 as combination therapy (part II), and to further investigate the safety, tolerability, PK and efficacy of the combination of ezabenlimab and BI 754111 at RD (part III).

Participant flow — Overall Study
MilestonePart I - ezabenlimab 240 mgPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mgPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort APart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort BPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort CPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D
Started733337372036
Treated633336372036
Completed00013303
Not completed733234342033
Withdrew: Progressive disease633230291730
Withdrew: Not treated10001000
Withdrew: Death00000011
Withdrew: Withdrawal by subject00002000
Withdrew: Adverse event00000522
Withdrew: Fatal adverse event: acute kidney injury00001000

Outcome measures

PrimaryPart I: Maximum Tolerated Dose (MTD) of Ezabenlimab

MTD is defined as the highest dose for a given schedule expected to cause \<25% risk of the true dose limiting toxicity (DLT) rate being ≥33% during the MTD evaluation period. Haematologic DLTs: any Grade 5 toxicity; neutropenia ≥Grade 4 for \>5 days; any duration Febrile neutropenia; grade 4 thrombocytopenia or Grade 3 with bleeding or requiring platelet transfusions (any Grade); unexplained Grade 4 anaemia or requiring blood transfusions (any Grade). Non-haematological DLTs: aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>3x Upper limit of normal (ULN) and total bilirubin \>2x ULN without cholestasis signs; any duration ≥Grade 4 AST or ALT; any ≥Grade 3 non-haematologic toxicity with exceptions; any Grade 4 or 5 adverse event; any duration any Grade 2 pneumonitis; any Grade 2 uveitis, eye pain, or blurred vision not improving to Grade 1 within 2 weeks or requiring systemic treatment; any ≥Grade 2 toxicity causing inability to administer trial drug on Cycle 2 Day 1.

Time frame:
First cycle of treatment: 3 weeks (21 days) following drug administration.
Reported as:
Number · Milligram
Part I: Maximum Tolerated Dose (MTD) of Ezabenlimab
MilligramPart I - ezabenlimab 240 mg
Part I: Maximum Tolerated Dose (MTD) of EzabenlimabNA
PrimaryPart I: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)

Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment) is reported.

Time frame:
First cycle of treatment: 3 weeks (21 days) following drug administration.
Reported as:
Count of participants · Participants
Part I: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)
ParticipantsPart I - ezabenlimab 240 mg
Part I: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)0
PrimaryPart II: MTD of the Ezabenlimab Plus BI 754111 Combination Therapy

MTD is defined as the highest dose for a given schedule expected to cause \<25% risk of the true DLT rate being ≥33% during the MTD evaluation period. Haematologic DLTs: any Grade 5 toxicity; neutropenia ≥Grade 4 for \>5 days; any duration Febrile neutropenia; grade 4 thrombocytopenia or Grade 3 with bleeding or requiring platelet transfusions (any Grade); unexplained Grade 4 anaemia or requiring blood transfusions (any Grade). Non-haematological DLTs: aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>3x Upper limit of normal (ULN) and total bilirubin \>2x ULN without cholestasis signs; any duration ≥Grade 4 AST or ALT; any ≥Grade 3 non-haematologic toxicity with exceptions; any Grade 4 or 5 adverse event; any duration any Grade 2 pneumonitis; any Grade 2 uveitis, eye pain, or blurred vision not improving to Grade 1 within 2 weeks or requiring systemic treatment; any ≥Grade 2 toxicity causing inability to administer trial drugs on Cycle 2 Day 1.

Time frame:
First cycle of treatment: 3 weeks (21 days) following drug administration.
Reported as:
Number · Milligram
Part II: MTD of the Ezabenlimab Plus BI 754111 Combination Therapy
MilligramPart II - ezabenlimab 240 mg + multiple BI 754111 doses
Part II: MTD of the Ezabenlimab Plus BI 754111 Combination TherapyNA
PrimaryPart II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)

Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment) is reported.

Time frame:
First cycle of treatment: 3 weeks (21 days) following drug administration.
Reported as:
Count of participants · Participants
Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)
ParticipantsPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mg
Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)000
PrimaryPart III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator

Number of patients with objective response (OR) - confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) Version 1.1 as assessed by the Investigator, is reported. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 49 months.
Reported as:
Count of participants · Participants
Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator
ParticipantsPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort APart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort BPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort CPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D
Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the Investigator4802
SecondaryPart III: Duration of Response

The duration of response, defined as the interval from the date of first documented PR or CR according to RECIST Version 1.1 as assessed by the Investigator, to the date of progressive disease (PD) or death, is reported. For all patients with an OR, the duration of OR was calculated as follows: * for patients with PD or death: duration of response \[days\] = date of outcome - date of first assessment indicating OR + 1, * for patients without PD or death: duration of response (censored) \[days\] = date of outcome - date of first assessment indicating OR + 1, for patients without disease progression or death. Kaplan-Meier estimates were used to calculate median duration of OR.

Time frame:
From the date of objective response until first date that death or PD has been documented, up to 1362 days.
Reported as:
Median · Days
Part III: Duration of Response
DaysPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort APart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort BPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort CPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D
Part III: Duration of Response478.0 (99.0 to 484.0)148.0 (100.0 to NA)44.0 (44.0 to 44.0)209.0 (126.0 to 292.0)
SecondaryPart III: Number of Patients With Disease Control

Number of patients with disease control is reported. Disease control: CR, PR, or stable disease (SD) according to RECIST Version 1.1 as assessed by the Investigator. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 49 months.
Reported as:
Count of participants · Participants
Part III: Number of Patients With Disease Control
ParticipantsPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort APart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort BPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort CPart III - ezabenlimab 240 mg + BI 754111 600 mg, cohort D
Part III: Number of Patients With Disease Control151697
SecondaryPart I: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator

Number of patients with OR: confirmed CR or PR according to RECIST v1.1 as assessed by the Investigator, is reported. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): 180 days.
Reported as:
Count of participants · Participants
Part I: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator
ParticipantsPart I - ezabenlimab 240 mg
Part I: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator0
SecondaryPart II: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator

Number of patients with OR: confirmed CR or PR according to RECIST v1.1 as assessed by the Investigator, is reported. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 389 days.
Reported as:
Count of participants · Participants
Part II: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator
ParticipantsPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mg
Part II: Number of Patients With OR: Confirmed CR or PR According to RECIST v1.1 as Assessed by the Investigator001
SecondaryPart I: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment

Maximum measured concentration of ezabenlimab in plasma (Cmax) in the first cycle of treatment (21 days following drug administration) is reported.

Time frame:
5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.
Reported as:
Geometric mean · microgram/milliliter
Part I: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment
microgram/milliliterPart I - ezabenlimab 240 mg
Part I: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment78.6 ± 33.7
SecondaryPart II: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment

Maximum measured concentration of ezabenlimab in plasma (Cmax) in the first cycle of treatment (21 days following drug administration) is reported.

Time frame:
5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.
Reported as:
Geometric mean · microgram/milliliter
Part II: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment
microgram/milliliterPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mg
Part II: Maximum Measured Concentration of Ezabenlimab in Plasma (Cmax) in the First Cycle of Treatment88.6 ± 15.8164 ± 16.593.3 ± 9.50
SecondaryPart II: Maximum Measured Concentration of BI 754111 in Plasma (Cmax) in the First Cycle of Treatment

Maximum measured concentration of BI 754111 in plasma (Cmax) in the first cycle of treatment (21 days following drug administration) is reported.

Time frame:
5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.
Reported as:
Geometric mean · microgram/milliliter
Part II: Maximum Measured Concentration of BI 754111 in Plasma (Cmax) in the First Cycle of Treatment
microgram/milliliterPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mg
Part II: Maximum Measured Concentration of BI 754111 in Plasma (Cmax) in the First Cycle of Treatment127 ± 11.0256 ± 23.0252 ± 6.52
SecondaryPart I: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment

Area under the concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) in the first cycle of treatment (21 days following drug administration) is reported.

Time frame:
5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.
Reported as:
Geometric mean · hour*microgram/milliliter
Part I: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment
hour*microgram/milliliterPart I - ezabenlimab 240 mg
Part I: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment15300 ± 46.8
SecondaryPart II: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment

Area under the concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) in the first cycle of treatment (21 days following drug administration) is reported.

Time frame:
5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.
Reported as:
Geometric mean · hour*microgram/milliliter
Part II: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment
hour*microgram/milliliterPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mg
Part II: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment17500 ± 22.126400 ± 12.518300 ± 5.18
SecondaryPart II: Area Under the Concentration-time Curve of BI 754111 in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment

Area under the concentration-time curve of BI 754111 in plasma over the time interval from 0 to 504 hours (AUC0-504) in the first cycle of treatment (21 days following drug administration) is reported.

Time frame:
5 minutes before drug administration and 1, 1.5, 2, 4, 7, 24, 48, 72, 168, 336 and 504 hours (h) after the start of drug administration in the first cycle of treatment.
Reported as:
Geometric mean · hour*microgram/milliliter
Part II: Area Under the Concentration-time Curve of BI 754111 in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment
hour*microgram/milliliterPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mg
Part II: Area Under the Concentration-time Curve of BI 754111 in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504) in the First Cycle of Treatment19900 ± 16.439400 ± 32.144200 ± 8.29

Adverse events

Collected over From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): 180 days (part I), up to 389 days (part II), up to approximately 49 months (part III). All-cause mortality was recorded from the start of treatment until the end of the follow-up period, up to approximately 49 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I - ezabenlimab 240 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Part II - ezabenlimab 240 mg + BI 754111 400 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part II - ezabenlimab 240 mg + BI 754111 600 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part II - ezabenlimab 240 mg + BI 754111 800 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part III - ezabenlimab 240 mg + BI 754111 600 mg3/129 (2.3%)36/129 (27.9%)100/129 (77.5%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventPart I - ezabenlimab 240 mgPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mgPart III - ezabenlimab 240 mg + BI 754111 600 mg
Infusion related reactionInjury, poisoning and procedural complications0/60/31/30/31/129
Decreased appetiteMetabolism and nutrition disorders1/61/30/30/31/129
Alanine aminotransferase increasedInvestigations0/60/30/31/30/129
Aspartate aminotransferase increasedInvestigations0/60/30/31/30/129
PneumoniaInfections and infestations1/60/30/30/36/129
Acute kidney injuryRenal and urinary disorders0/60/30/30/33/129
Febrile neutropeniaBlood and lymphatic system disorders0/60/30/30/32/129
HyperthyroidismEndocrine disorders0/60/30/30/32/129
Oesophageal ruptureGastrointestinal disorders0/60/30/30/32/129
CholangitisHepatobiliary disorders0/60/30/30/32/129
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPart I - ezabenlimab 240 mgPart II - ezabenlimab 240 mg + BI 754111 400 mgPart II - ezabenlimab 240 mg + BI 754111 600 mgPart II - ezabenlimab 240 mg + BI 754111 800 mgPart III - ezabenlimab 240 mg + BI 754111 600 mg
MalaiseGeneral disorders1/63/30/30/30/129
HypothyroidismEndocrine disorders0/62/30/30/311/129
NauseaGastrointestinal disorders0/61/32/30/312/129
PyrexiaGeneral disorders0/60/32/32/332/129
Decreased appetiteMetabolism and nutrition disorders1/62/30/30/322/129
VomitingGastrointestinal disorders0/60/32/30/30/129
FatigueGeneral disorders3/60/30/30/313/129
AnaemiaBlood and lymphatic system disorders2/60/30/31/318/129
DiarrhoeaGastrointestinal disorders2/61/30/30/311/129
Back painMusculoskeletal and connective tissue disorders0/60/31/30/38/129

Baseline characteristics

Treated set (TS): TS included all patients who were documented to have received at least one dose of ezabenlimab or BI 754111. The TS was used for both efficacy and safety analyses.

Age, Continuous
Age, Continuous(Years)Part I - Ezabenlimab 240 mgPart II - Ezabenlimab 240 mg + BI 754111 400 mgPart II - Ezabenlimab 240 mg + BI 754111 600 mgPart II - Ezabenlimab 240 mg + BI 754111 800 mgPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort APart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort BPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort CPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort DTotal
Mean55.3 ± 15.265.0 ± 6.259.0 ± 16.145.7 ± 26.357.2 ± 14.062.5 ± 8.658.9 ± 12.960.5 ± 10.459.5 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Part I - Ezabenlimab 240 mgPart II - Ezabenlimab 240 mg + BI 754111 400 mgPart II - Ezabenlimab 240 mg + BI 754111 600 mgPart II - Ezabenlimab 240 mg + BI 754111 800 mgPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort APart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort BPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort CPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort DTotal
Female21311062732
Male420226311829112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part I - Ezabenlimab 240 mgPart II - Ezabenlimab 240 mg + BI 754111 400 mgPart II - Ezabenlimab 240 mg + BI 754111 600 mgPart II - Ezabenlimab 240 mg + BI 754111 800 mgPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort APart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort BPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort CPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort DTotal
Asian633336372036144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part I - Ezabenlimab 240 mgPart II - Ezabenlimab 240 mg + BI 754111 400 mgPart II - Ezabenlimab 240 mg + BI 754111 600 mgPart II - Ezabenlimab 240 mg + BI 754111 800 mgPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort APart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort BPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort CPart III - Ezabenlimab 240 mg + BI 754111 600 mg, Cohort DTotal
Not Hispanic or Latino633336372036144
08

Study locations

13 sites
  • National Cancer Center Hospital East
    Chiba, Kashiwa, 277-8577, Japan
  • Kanagawa Cancer Center
    Kanagawa, Yokohama, 241-8515, Japan
  • Saitama Cancer Center
    Saitama, Kitaadachi-gun, 362-0806, Japan
  • Shizuoka Cancer Center
    Shizuoka, Sunto-gun, 411-8777, Japan
  • National Cancer Center Hospital
    Tokyo, Chuo-ku, 104-0045, Japan
  • Japanese Foundation for Cancer Research
    Tokyo, Koto-ku, 135-8550, Japan
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • NCKUH
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Chang Gung Memorial Hospital(Linkou)
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Zettl M, Wurm M, Schaaf O, Mostbock S, Tirapu I, Apfler I, Lorenz IC, Frego L, Kenny C, Thibodeau M, Oquendo Cifuentes E, Reschke M, Moll J, Kraut N, Vogt A, Sedgwick JD, Waizenegger IC. Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. Oncoimmunology. 2022 Jun 16;11(1):2080328. doi: 10.1080/2162402X.2022.2080328. eCollection 2022. PubMed 35756842 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jul 2023, 64 months.

Results were first posted in Dec 2025, 2 years 4 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 64 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 15, 2018
StartActual
Feb 23, 2018
Primary completionActual
Jul 20, 2023
CompletionActual
Jul 20, 2023
Results first posted
Dec 19, 2025
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03433898
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
Feb 23, 2018
Primary completion
Jul 20, 2023
Completion
Jul 20, 2023
Results posted
Dec 19, 2025
Last update
Dec 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezabenlimab

Start the discussion